Table 3. Factors associated with usage of chemotherapy for patients with surgically resected intrahepatic cholangiocarcinoma.
| Characteristics | OR | 95% confidence interval |
|---|---|---|
| Age (years) | ||
| 18–49 | REF | – |
| 50–59 | 0.69 | 0.46–1.03 |
| 60–69 | 0.63* | 0.43–0.93 |
| 70+ | 0.28* | 0.19–0.42 |
| Gender | ||
| Female | REF | – |
| Male | 0.68* | 0.54–0.87 |
| Race | ||
| Non-Hispanic White | REF | – |
| Black | 0.59* | 0.35–0.98 |
| Others | 0.93 | 0.66–1.31 |
| Years of diagnosis | ||
| 2000–2008 | REF | – |
| 2009–2014 | 1.64* | 1.24–2.16 |
| Grades | ||
| I | REF | – |
| II | 0.95 | 0.64–1.42 |
| III | 0.91 | 0.58–1.40 |
| Missing | 0.92 | 0.59–1.42 |
| Nodes evaluated | ||
| None/unknown | REF | – |
| 1–5 | 1.77 | 0.58–5.36 |
| 6+ | 1.41 | 0.44–4.49 |
| Lymph node status | ||
| LN− | 0.69 | 0.22–2.12 |
| LN+ | 1.26 | 0.41–3.91 |
| None/unknown | REF | – |
| T stages | ||
| I | REF | – |
| II | 1.24 | 0.90–1.71 |
| III and IV | 1.87* | 1.36–2.57 |
| Missing | 1.29 | 0.86–1.93 |
*, statistically significant. LN, lymph node; OR, odds ratio; REF, reference comparative factor.